Yinling Qushi Granule as a therapeutic agent for metabolic syndrome: pharmacological, molecular targets, and pharmacokinetic insights

Abstract

Metabolic Syndrome (MetS) is a globally prevalent condition with unclear underlying mechanisms. Current treatments primarily focus on alleviating individual symptoms, lacking long-term therapeutic strategies that target the disease’s endotypes. In this study, we found that Yinling Qushi Granule (YLQSG), a formulated prescription for treating Dampness Syndrome (DS) in Traditional Chinese Medicine (TCM), effectively attenuated hypertension associated with MetS. After 12 weeks of YLQSG treatment, MetS patients showed significant reduction in systolic and diastolic blood pressure, body mass index (BMI) and glycated hemoglobin (HbA1c). Chemical analysis has identified a total of 96 components of YLQSG, alongside with 27 serum absorbed prototypes and 13 metabolites. In vivo metabolic profiling revealed critical Phase I metabolism including dehydration, demethylation, and oxidation. By integrating network pharmacology and molecular docking, we proposed 11 triterpenoids from the sovereign herb Poria cocos (Schw.) Wolf as active constituents of YLQSG. These triterpenoids showed potent binding affinities with AGTR1 and 11β-HSD1, two crucial druggable targets in the renin–angiotensin–aldosterone system. Pharmacokinetics of these 11 lanosterol-type triterpenoids in rat serum indicated their good drug likeness properties. In summary, our findings highlight the potential of YLQSG in treating MetS, particularly hypertension, and identify its active compounds and potential molecular targets, offering a promising alternative strategy for the long-term management of MetS.

Trial registration

ChiCTR, ChiCTR2200063506. Registered 9 September 2022, https://www.chictr.org.cn/showproj.html?proj=174653.

Keywords

Yinling-Qushi Granule / Metabolic syndrome / Hypertension / Dampness syndrome / Lanosterol-triterpenoids / Medical and Health Sciences / Cardiorespiratory Medicine and Haematology

References

[1] AguilarM, BhuketT, TorresS, LiuB, WongRJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA, 2015, 313: 1973-1974.

[2] AmbergerJS, BocchiniCA, ScottAF, HamoshA. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res, 2019, 47: D1038-d1043.

[3] BarzilayJI, DavisBR, CutlerJA, PresselSL, WheltonPK, BasileJ, MargolisKL, OngST, SadlerLS, SummersonJ. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med, 2006, 166: 2191-2201.

[4] BenetLZ. Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm, 1978, 6: 559-585.

[5] CaiTG, CaiY. Triterpenoids from the fungus Poria cocos and their inhibitory activity on nitric oxide production in mouse macrophages via blockade of activating protein-1 pathway. Chem Biodivers, 2011, 8: 2135-2143.

[6] ChenG, McAlisterFA, WalkerRL, HemmelgarnBR, CampbellNR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension, 2011, 57: 891-897.

[7] ChenB, ZhangJ, HanJ, ZhaoR, BaoL, HuangY, LiuH. Lanostane triterpenoids with glucose-uptake-stimulatory activity from peels of the cultivated edible mushroom Wolfiporia cocos. J Agric Food Chem, 2019, 67: 7348-7364.

[8] ChenDQ, WangYN, VaziriND, ChenL, HuHH, ZhaoYY. Poricoic acid A activates AMPK to attenuate fibroblast activation and abnormal extracellular matrix remodelling in renal fibrosis. Phytomedicine, 2020, 72: 153232.

[9] ChengS, EliazI, LinJ, Thyagarajan-SahuA, SlivaD. Triterpenoids from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. Int J Oncol, 2013, 42: 1869-1874.

[10] ChengS, SwansonK, EliazI, McClintickJN, SanduskyGE, SlivaD. Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress. PLoS One, 2015, 10: e0122270.

[11] CornierMA, DabeleaD, HernandezTL, LindstromRC, SteigAJ, StobNR, Van PeltRE, WangH, EckelRH. The metabolic syndrome. Endocr Rev, 2008, 29: 777-822.

[12] CushmanWC, GrimmRHJr, CutlerJA, EvansGW, CapesS, CorsonMA, SadlerLS, AldermanMH, PetersonK, BertoniA, BasileJN. Rationale and design for the blood pressure intervention of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol, 2007, 99: 44i-55i.

[13] CushmanWC, EvansGW, ByingtonRP, GoffDCJr, GrimmRHJr, CutlerJA, Simons-MortonDG, BasileJN, CorsonMA, ProbstfieldJL, KatzL, PetersonKA, FriedewaldWT, BuseJB, BiggerJT, GersteinHC, Ismail-BeigiF. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 2010, 362: 1575-1585.

[14] DaiJ, SunS, CaoJ, ZhaoY, CaoH, ZhengN, FangJ, WangY, ZhangW, ZhangY, HuY, CaoZ. Similar connotation in chronic hepatitis b and nonalcoholic fatty liver patients with dampness-heat syndrome. Evid Based Complement Alternat Med, 2013, 2013. 793820

[15] DainaA, MichielinO, ZoeteV. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res, 2019, 47: W357-w364.

[16] DingX, LiS, HuangH, ShenJ, DingY, ChenT, MaL, LiuJ, LaiY, ChenB, WangY, TanQ. Bioactive triterpenoid compounds of Poria cocos (Schw.) Wolf in the treatment of diabetic ulcers via regulating the PI3K-AKT signaling pathway. J Ethnopharmacol., 2024, 325. 117812

[17] DouZ, XiaY, ZhangJ, LiY, ZhangY, ZhaoL, HuangZ, SunH, WuL, HanD, LiuY. Syndrome differentiation and treatment regularity in traditional Chinese medicine for type 2 diabetes: A text mining analysis. Front Endocrinol (Lausanne), 2021, 12. 728032

[18] EberhardtJ, Santos-MartinsD, TillackAF, ForliS. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model, 2021, 61: 3891-3898.

[19] FengG, LiS, LiuS, SongF, PiZ, LiuZ. Targeted screening approach to systematically identify the absorbed effect substances of Poria cocos in vivo using ultrahigh performance liquid chromatography tandem mass spectrometry. J Agric Food Chem, 2018, 66: 8319-8327.

[20] FordES, GilesWH, DietzWH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA, 2002, 287: 356-359.

[21] GathercoleLL, LaveryGG, MorganSA, CooperMS, SinclairAJ, TomlinsonJW, StewartPM. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev, 2013, 34: 525-555.

[22] Giner-LarzaEM, MáñezS, Giner-PonsRM, Carmen RecioM, RíosJL. On the anti-inflammatory and anti-phospholipase A(2) activity of extracts from lanostane-rich species. J Ethnopharmacol, 2000, 73: 61-69.

[23] GoddardZR, SearceyM, OsbournA. Advances in triterpenoid drug discovery. Trends Pharmacol Sci, 2024, 45: 964-968.

[24] GreenJB, BethelMA, PaulSK, RingA, KaufmanKD, ShapiroDR, CaliffRM, HolmanRR. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J, 2013, 166: 983-989.e987.

[25] GreenJB, BethelMA, ArmstrongPW, BuseJB, EngelSS, GargJ, JosseR, KaufmanKD, KoglinJ, KornS, LachinJM, McGuireDK, PencinaMJ, StandlE, SteinPP, SuryawanshiS, Van de WerfF, PetersonED, HolmanRR. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015, 373: 232-242.

[26] GressTW, NietoFJ, ShaharE, WoffordMR, BrancatiFL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med., 2000, 342: 905-912.

[27] GrundySM, CleemanJI, DanielsSR, DonatoKA, EckelRH, FranklinBA, GordonDJ, KraussRM, SavagePJ, SmithSCJr, SpertusJA, CostaF. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation, 2005, 112: 2735-2752.

[28] GuiY, SunL, LiuR, LuoJ. Pachymic acid inhibits inflammation and cell apoptosis in lipopolysaccharide (LPS)-induced rat model with pneumonia by regulating NF-κB and MAPK pathways. Allergol Immunopathol (Madr), 2021, 49: 87-93.

[29] Guo ZY, Wu X, Zhang SJ, Yang JH, Miao H, Zhao YY. Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology. Acta Pharmacol Sin. 2024; 0: 1–16.

[30] GuoZ, YuS, GuanY, LiYY, LuYY, ZhangH, SuSB. Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis b and liver cirrhosis. Evid Based Complement Alternat Med, 2012, 2012. 120350

[31] GuoY, HeJ, LiS, ZouS, ZhangH, YangX, WangJ. Warm and humid environment induces gut microbiota dysbiosis and bacterial translocation leading to inflammatory state and promotes proliferation and biofilm formation of certain bacteria, potentially causing sticky stool. BMC Microbiol, 2025, 25: 24.

[32] HanssonL, ZanchettiA, CarruthersSG, DahlöfB, ElmfeldtD, JuliusS, MénardJ, RahnKH, WedelH, WesterlingS. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351: 1755-1762.

[33] Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259.

[34] HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359: 1577-1589.

[35] HolmanRR, PaulSK, BethelMA, NeilHA, MatthewsDR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med, 2008, 359: 1565-1576.

[36] HultM, ShafqatN, EllebyB, MitschkeD, SvenssonS, ForsgrenM, BarfT, VallgårdaJ, AbrahmsenL, OppermannU. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol Cell Endocrinol, 2006, 248: 26-33.

[37] Hypertension in Diabetes Study Group (HDSG). Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade. Diabet Med. 1994;11:773–782.

[38] JiangM, LuC, ZhangC, YangJ, TanY, LuA, ChanK. Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol, 2012, 140: 634-642.

[39] JiangK, JiangQ, MoX, LiJ, HuH, HuangQ, GuoW, QiuT, RenJ, ZhangL, XieY, HuangK. Study on the characteristics of gut microbiota in chronic hepatitis b patients with damp heat syndrome and liver depression and spleen deficiency syndrome. World J Integr Tradit Western Med, 2021, 7: 46-54

[40] JinJ, ZhouR, XieJ, YeH, LiangX, ZhongC, ShenB, QinY, ZhangS, HuangL. Insights into triterpenoid acids in fermented mycelia of edible fungus Poria cocos by a comparative study. Molecules, 2019, 24: 1-11.

[41] KöhlerS, GarganoM, MatentzogluN, CarmodyLC, Lewis-SmithD, VasilevskyNA, DanisD, BalaguraG, BaynamG, BrowerAM, CallahanTJ, ChuteCG, EstJL, GalerPD, GanesanS, GrieseM, HaimelM, PazmandiJ, HanauerM, HarrisNL, HartnettMJ, HastreiterM, HauckF, HeY, JeskeT, KearneyH, KindleG, KleinC, KnoflachK, KrauseR, LagorceD, McMurryJA, MillerJA, Munoz-TorresMC, PetersRL, RappCK, RathAM, RindSA, RosenbergAZ, SegalMM, SeidelMG, SmedleyD, TalmyT, ThomasY, WiafeSA, XianJ, YükselZ, HelbigI, MungallCJ, HaendelMA, RobinsonPN. The human phenotype ontology in 2021. Nucleic Acids Res, 2021, 49: D1207-d1217.

[42] LakkaHM, LaaksonenDE, LakkaTA, NiskanenLK, KumpusaloE, TuomilehtoJ, SalonenJT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002, 288: 2709-2716.

[43] LiTH, HouCC, ChangCL, YangWC. Anti-hyperglycemic properties of crude extract and triterpenoids from Poria cocos. Evid Based Complement Alternat Med, 2011, 2011: 1-8.

[44] LiB, SuY, XiangN, QinB, LiG, WanT, LiuX, WangD, JiangC, WenL, FengQS. Comparative serum microRNA array analysis of the spleen-stomach dampness-heat syndrome in different diseases: Chronic hepatitis b and chronic gastritis. Anat Rec (Hoboken), 2021, 304: 2620-2631.

[45] LiuH, JingN, LiF, WangK, TangJ, ZhaoQ, ZhangY, NoushahiHA, XuR, WangX, ZhuW, FengS, ShuS, MeiZ. An omics-based characterization of Wolfiporia cocos reveals three CYP450 members involved in the biosynthetic pathway of pachymic acid. Commun Biol, 2024, 7: 666.

[46] LiuT, WangJ, TongY, WuL, XieY, HeP, LinS, HuX. Integrating network pharmacology and animal experimental validation to investigate the action mechanism of oleanolic acid in obesity. J Transl Med, 2024, 22: 86.

[47] LovreD, Mauvais-JarvisF. Trends in prevalence of the metabolic syndrome. JAMA, 2015, 314: 950.

[48] LuM, YinJ, XuT, DaiX, LiuT, ZhangY, WangS, LiuY, ShiH, ZhangY, MoF, SukhorukovV, OrekhovAN, GaoS, WangL, ZhangD. Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice. J Ethnopharmacol, 2024, 319. 117262

[49] NeelandIJ, LimS, TchernofA, GastaldelliA, RangaswamiJ, NdumeleCE, Powell-WileyTM, DesprésJP. Metabolic syndrome. Nat Rev Dis Primers, 2024, 10: 77.

[50] NgCYJ, LaiNPY, NgWM, SiahKTH, GanRY, ZhongLLD. Chemical structures, extraction and analysis technologies, and bioactivities of edible fungal polysaccharides from Poria cocos: An updated review. Int J Biol Macromol, 2024, 261. 129555

[51] NogalesC, MamdouhZM, ListM, KielC, CasasAI, SchmidtH. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci, 2022, 43: 136-150.

[52] PagidipatiNJ, NavarAM, PieperKS, GreenJB, BethelMA, ArmstrongPW, JosseRG, McGuireDK, LokhnyginaY, CornelJH, HalvorsenS, StrandbergTE, DelibasiT, HolmanRR, PetersonED. Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: International insights from the TECOS trial (trial evaluating cardiovascular outcomes with sitagliptin). Circulation, 2017, 136: 1193-1203.

[53] ParatiG, BiloG, OchoaJE. Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care, 2011, 34Suppl 2S297-303.

[54] RíosJL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med, 2011, 77: 681-691.

[55] RydénL, StandlE, BartnikM, Van den BergheG, BetteridgeJ, de BoerMJ, CosentinoF, JönssonB, LaaksoM, MalmbergK, PrioriS, OstergrenJ, TuomilehtoJ, ThrainsdottirI, VanhorebeekI, Stramba-BadialeM, LindgrenP, QiaoQ, PrioriSG, BlancJJ, BudajA, CammJ, DeanV, DeckersJ, DicksteinK, LekakisJ, McGregorK, MetraM, MoraisJ, OsterspeyA, TamargoJ, ZamoranoJL, DeckersJW, BertrandM, CharbonnelB, ErdmannE, FerranniniE, FlyvbjergA, GohlkeH, JuanateyJR, GrahamI, MonteiroPF, ParhoferK, PyöräläK, RazI, SchernthanerG, VolpeM, WoodD. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J, 2007, 28: 88-136

[56] ShangH, ZhangL, XiaoT, ZhangL, RuanJ, ZhangQ, LiuK, YuZ, NiY, WangB. Study on the differences of gut microbiota composition between phlegm-dampness syndrome and qi-yin deficiency syndrome in patients with metabolic syndrome. Front Endocrinol (Lausanne), 2022, 13: 1063579.

[57] ShannonP, MarkielA, OzierO, BaligaNS, WangJT, RamageD, AminN, SchwikowskiB, IdekerT. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13: 2498-2504.

[58] StamlerJ, VaccaroO, NeatonJD, WentworthD. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care, 1993, 16: 434-444.

[59] StewartPM, WallaceAM, ValentinoR, BurtD, ShackletonCH, EdwardsCR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet, 1987, 2: 821-824.

[60] SunY. Biological activities and potential health benefits of polysaccharides from Poria cocos and their derivatives. Int J Biol Macromol, 2014, 68: 131-134.

[61] SunSS, WangK, MaK, BaoL, LiuHW. An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota. Chin J Nat Med, 2019, 17: 3-14

[62] SzklarczykD, KirschR, KoutrouliM, NastouK, MehryaryF, HachilifR, GableAL, FangT, DonchevaNT, PyysaloS, BorkP, JensenLJ, von MeringC. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res, 2023, 51: D638-d646.

[63] TomlinsonJW, WalkerEA, BujalskaIJ, DraperN, LaveryGG, CooperMS, HewisonM, StewartPM. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev, 2004, 25: 831-866.

[64] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study Group. Bmj, 1998, 317: 703-713.

[65] WamilM, SecklJR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today, 2007, 12: 504-520.

[66] WangYZ, ZhangJ, ZhaoYL, LiT, ShenT, LiJQ, LiWY, LiuHG. Mycology, cultivation, traditional uses, phytochemistry and pharmacology of Wolfiporia cocos (Schwein.) Ryvarden et Gilb.: a review. J Ethnopharmacol., 2013, 147: 265-276.

[67] WenL, JiangC, WanTJ, WangD, YanD, LiGY, SuY, LiuXY, RongLJ, YeH, LiBX, FengQS. Biological differentiation of dampness-heat syndromes in chronic hepatitis b: from comparative microRNA microarray profiling to biomarker identification. Evid Based Complement Alternat Med, 2020, 2020: 7234893.

[68] WuZL, RenH, LaiWY, LinS, JiangRY, YeTC, ShenQB, ZengQC, XuDL. Sclederma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure. J Ethnopharmacol, 2014, 155: 563-571.

[69] YangM, ZhaoY, QinY, XuR, YangZ, PengH. Untargeted metabolomics and targeted quantitative analysis of temporal and spatial variations in specialized metabolites accumulation in Poria cocos (Schw.) Wolf (Fushen). Front Plant Sci, 2021, 12: 713490.

[70] YangL, YuH, HouA, ManW, WangS, ZhangJ, WangX, ZhengS, JiangH, KuangH. A review of the ethnopharmacology, phytochemistry, pharmacology, application, quality control, processing, toxicology, and pharmacokinetics of the dried rhizome of Atractylodes macrocephala. Front Pharmacol, 2021, 12: 727154.

[71] YuH, KimPM, SprecherE, TrifonovV, GersteinM. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol, 2007, 3: e59.

[72] ZhangZ, YangS, LinX, HuangY, WeiX, ZhouJ, LiR, DengB, FuC. Metabolomics of spleen-yang deficiency syndrome and the therapeutic effect of Fuzi Lizhong pill on regulating endogenous metabolism. J Ethnopharmacol, 2021, 278: 114281.

[73] ZhouH, ZhangW, CaiX, YangS, LiuA, ZhouX, CaiJ, WuD, ZengH. Unraveling the link between hypertriglyceridemia, dampness syndrome, and chronic diseases: a comprehensive observational study. Medicine (Baltimore), 2024, 103: e39207.

Funding

Key Project of State Key Laboratory of Dampness Syndrome of Chinese Medicine(No.SZ2021ZZ32)

Science and Technology Planning Project of Guangdong Province(No. 2023B1212060063)

RIGHTS & PERMISSIONS

The Author(s)